ANTI-IL-6 ANTIBODY CLAZAKIZUMAB IN LATE ANTIBODY-MEDIATED REJECTION - MOLECULAR REBOUND PHENOMENA UNDER IL-6 BLOCKADE?

被引：0
|
作者：
Borski, Anita [1 ]
Haindl, Susanne [2 ]
Durr, Michael [3 ]
Budde, Klemens [3 ]
Schranz, Sabine [1 ]
Eskandary, Farsad A. [2 ]
Doberer, Konstantin [2 ]
Halloran, Philip F. [4 ]
Chong, Edward [5 ]
Jilma, Bernd [1 ]
Bohmig, Georg A. [2 ]
Wahrmann, Markus [2 ]
机构：
[1] Med Univ Vienna, Dept Clin Pharmacol, Vienna, Austria
[2] Med Univ Vienna, Dept Med 3, Vienna, Austria
[3] Charite Univ Med Berlin, Dept Nephrol & Med Intens Care, Berlin, Germany
[4] Univ Alberta, Dept Med, Edmonton, AB, Canada
[5] Vitaeris Inc, Vancouver, BC, Canada
来源：
TRANSPLANTATION | 2020年 / 104卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
380.1
引用
收藏
页码：S67 / S67
页数：1
相关论文
共 50 条
  • [1] Anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Rejection - Molecular Rebound Phenomena Under IL-6 Blockade?
    Borski, A.
    Haindl, S.
    Duerr, M.
    Budde, K.
    Schranz, S.
    Eskandary, F. A.
    Doberer, K.
    Halloran, P. F.
    Chong, E.
    Jilma, B.
    Boehmig, G. A.
    Wahrmann, M.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2020, 20 : 853 - 853
  • [2] A Randomized Clinical Trial of Anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Kidney Transplant Rejection
    Doberer, Konstantin
    Duerr, Michael
    Halloran, Philip F.
    Eskandary, Farsad
    Budde, Klemens
    Regele, Heinz
    Reeve, Jeff
    Borski, Anita
    Kozakowski, Nicolas
    Reindl-Schwaighofer, Roman
    Waiser, Johannes
    Lachmann, Nils
    Schranz, Sabine
    Firbas, Christa
    Muehlbacher, Jakob
    Gelbenegger, Georg
    Perkmann, Thomas
    Wahrmann, Markus
    Kainz, Alexander
    Ristl, Robin
    Halleck, Fabian
    Bond, Gregor
    Chong, Edward
    Jilma, Bernd
    Boehmig, Georg A.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (03): : 708 - 722
  • [3] CLAZAKIZUMAB (CLZ, ANTI-IL-6) AND TOCILIZUMAB (TCZ, ANTI-IL-6 RECEPTOR) DIFFERENTIALLY AFFECT IL-6/IL-6R SIGNALING BY MODULATING SOLUBLE IL-6R & GP130 IN PATIENTS TREATED FOR CHRONIC ANTIBODY-MEDIATED REJECTION (CABMR)
    Shin, Bongha
    Vo, Ashley
    Ge, Shili
    Petrosyan, Anna
    Ammerman, Noriko
    Jordan, Stanley
    Toyoda, Mieko
    TRANSPLANT INTERNATIONAL, 2019, 32 : 410 - 410
  • [4] EVALUATION OF CLAZAKIZUMAB (ANTI-IL-6) FOR TREATMENT OF KIDNEY TRANSPLANT RECIPIENTS WITH CHRONIC & ACTIVE ANTIBODY MEDIATED REJECTION
    Jordan, Stanley
    Ammerman, Noriko
    Toyoda, Mieko
    Huang, Edmund
    Nast, Cynthia
    Peng, Alice
    Sethi, Supreet
    Najjar, Reiad
    Kim, Irene
    Lim, Kathlyn
    Choi, Jua
    Vo, Ashley
    TRANSPLANT INTERNATIONAL, 2019, 32 : 400 - 401
  • [5] Anti-IL-6 receptor antibody increases blood IL-6 level via the blockade of IL-6 clearance, but not via the induction of IL-6 production
    Uchiyama, Yasushi
    Yoshida, Hiroto
    Koike, Nobuo
    Hayakawa, Naohiko
    Sugita, Atsuko
    Nishimura, Takashi
    Mihara, Masahiko
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2008, 8 (11) : 1595 - 1601
  • [6] Clazakizumab (CLZ, Anti-IL-6 Antibody) and Tocilizumab (TCZ, Anti-IL-6 Receptor [r] Antibody) Treatments Differentially Affect IL-6/IL-6R Signaling by Modulating Soluble IL-6R (sIL-6R) and gp130 (sgp130) in Kidney Transplant Patients (KTx Pts) Treated for Chronic Antibody-Mediated Rejection (cABMR).
    Shin, B.
    Ge, S.
    Petrosyan, A.
    Ammerman, N. F.
    Vo, A. A.
    Jordan, S. C.
    Toyoda, M.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2019, 19 : 452 - 452
  • [7] Anti-interleukin-6 Antibody Clazakizumab in Antibody-mediated Renal Allograft Rejection: Accumulation of Antibody-neutralized Interleukin-6 Without Signs of Proinflammatory Rebound Phenomena
    Borski, Anita
    Eskandary, Farsad
    Haindl, Susanne
    Doberer, Konstantin
    Muehlbacher, Jakob
    Mayer, Katharina A.
    Budde, Klemens
    Halloran, Philip F.
    Chong, Edward
    Jilma, Bernd
    Boehmig, Georg A.
    Wahrmann, Markus
    TRANSPLANTATION, 2023, 107 (02) : 495 - 503
  • [8] CLAZAKIZUMAB (ANTI-IL-6 MONOCLONAL) TREATMENT OF PATIENTS WITH CHRONIC & ACTIVE ANTIBODY-MEDIATED REJECTION POST-KIDNEY TRANSPLANTATION (NCT03380377)
    Jordan, Stanley
    Ammerman, Noriko
    Toyoda, Mieko
    Ge, Shili
    Huang, Edmund
    Peng, Alice
    Sethi, Supreet
    Najjar, Reiad
    Ortiz, Edwin
    Chu, Maggie
    De Guzman, Abner
    Kim, Irene
    Lim, Kathlyn
    Choi, Jua
    Vo, Ashley A.
    TRANSPLANTATION, 2020, 104 (09) : S67 - S68
  • [9] Blockade of IL-6/IL-6R Signaling Attenuates Acute Antibody-Mediated Rejection in a Mouse Cardiac Transplantation Model
    Ma, Maolin
    Sun, Qipeng
    Li, Xiujie
    Deng, Gengguo
    Zhang, Yannan
    Yang, Zhe
    Han, Fei
    Huang, Zhengyu
    Fang, Youqiang
    Liao, Tao
    Sun, Qiquan
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [10] Clazakizumab (CLZ, Anti-IL-6 Monoclonal Antibody) Treatment of Patients (Pts) with Chronic Antibody-Mediated Rejection (cABMR) Reduces Total Immunoglobulin (Ig) and Anti-HLA IgG Antibody Levels.
    Shin, B.
    Ammerman, N. F.
    Vo, A. A.
    Zhang, X.
    Jordan, S. C.
    Toyoda, M.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2019, 19 : 667 - 667
12345